Diseases and Conditions

We have identified a number of immuno-inflammatory conditions where treatment gaps exist, and we seek to apply our revelationary science to fill these treatment gaps.

Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is the most common form of autoimmune arthritis. It affects more than 1.3 million Americans. About 75% of patients with RA are women, and 1-3% of women may get RA in their lifetime. The disease most often begins between the ages of 30 and 50, and is a chronic disease which causes joint pain, stiffness, swelling and decreased movement of the joints. Small joints in the hands and feet are most commonly affected, but RA can also affect organs, such as eyes, skin or lungs.

Great progress has been made in the treatment of RA with the advent of biological therapies and JAK inhibitors.  There remains a need for small molecule therapies with improved benefit:risk profiles that can make safe and effective therapy accessible to more patients.

Atopic Dermatitis

Atopic Dermatitis (AD) is a chronic, inflammatory skin disease that usually starts in early infancy. In developed countries, AD affects 15-30% of children and 2-10% of adults. The predominant symptom is a red, itchy rash, which can have a significant impact on quality of life.

Topical steroids have been a mainstay of AD treatment for decades, but are associated with significant adverse events which may limit how much or how long they can be used. JAK inhibitors may offer a good alternative treatment option for AD. The challenge is to optimize delivery of the drug to the disease site (i.e., the skin) while minimizing systemic toxicity.

Psoriasis

Psoriasis is a chronic, inflammatory disease. It most commonly presents in the form of scaly plaques on the skin of the elbows, knees, scalp and intergluteal clefts. In up to 30% of patients, it can also be associated with arthritis. Approximately 2% of the population has psoriasis, with a slightly higher incidence in women than in men.

Both biologic and immunomodulatory therapies may be used safely and effectively.

New biological therapies have been very effective in the treatment of psoriasis, but a relatively small proportion of patients with psoriasis are treated with these medicines.  A small molecule oral medicine that could target these same biological pathways could address an unmet need to a large number of patients.     

Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) is an inflammatory disease affecting the gastrointestinal (GI) tract.  The two major types of IBD are ulcerative colitis, and Crohn’s disease: Ulcerative Colitis is limited to the colon, while Crohn’s Disease can impact any segment of the GI tract.  Approximately 1-2 million people in the United States have IBD.  IBD most commonly presents in young adults (late adolescence to the third decade of life) and males and females are affected at a similar rate.

While the use of biological therapies have improved the medical treatment of IBD, there remains a great need for more effective therapies with an improved safety profile.